Genetic Resilience: Nature's Blueprint for Prevention
We don't ask what makes people sick. We discover why some people stay well — despite the odds.
Traditional approach: What makes people sick
Halia's approach: Why people stay well
Outcome: Faster, higher-confidence resilience-driven discovery
Uncovering Nature's Built-In Defenses
At Halia Therapeutics, we shift the paradigm from treating illness to understanding resilience. Using population-scale pedigrees and genetic data, we uncover protective factors that help some individuals resist disease - even with high-risk genotypes or environmental triggers.
GENMOR: Pinpointing Nature's Protective Variants
Process Flow:
- Leverage UPDB genealogies and health records
- Identify disease-discordant families
- Perform genome-wide comparative analysis
Benefits:
- Uncovers resilience loci like RAB10
- Yields novel, biology-backed drug targets
- Enables proactive prevention strategies
Our Resilience-First Clinical Programs
Alzheimer's
Some APOE4 carriers avoid Alzheimer's due to protective mutations. Halia identified and is targeting RAB10 based on these findings.
MIDS
Resilience variants show immune system restoration via NEK7 inhibition, forming the foundation for HT-6184.
Obesity
In preclinical models, HT-6184 enhances semaglutide efficacy while preserving lean mass.
Performance Metrics
Time-to-Phase 2B: ⅓ industry averageSignificant cost savings per program
Alzheimer's
Some APOE4 carriers avoid Alzheimer's due to protective mutations. Halia identified and is targeting RAB10 based on these findings.
MIDS
Resilience variants show immune system restoration via NEK7 inhibition, forming the foundation for HT-6184.
Obesity
In preclinical models, HT-6184 enhances semaglutide efficacy while preserving lean mass.
Performance Metrics
Time-to-Phase 2B: ⅓ industry averageSignificant cost savings per program
Re-Targeting Resilience at Scale
GENMOR-AI™ empowers rapid, iterative discovery
3-Step Process:
- Integrate genomic and phenomic data
- Al-driven interaction modeling
- Automated prioritization of resilience factors
Benefits:
- Reduces discovery timelines by ≥50%
- Continuously refines hypotheses
- Feeds top targets directly into GENMOR workflows
This is the Company AI Was Built For
Five Core Capabilities:
Data Integration: Al synthesizes multi-modal datasets Pattern
Detection: Deep learning finds missed protective patterns
Speed: Fast, iterative retraining
Precision: Resilient families reduce biological noise
Scalability: Works across Alzheimer's, oncology, and metabolic disease
The Future of Resilience-First Medicine
We're building a next-generation drug development model — one that start with nature's own solutions. From genomic analysis to clinical translation, Halia's approach turn insights from resilient individuals into powerful therapies for everyone.
Greater weight loss was achieved when HT-6184 was combined with semaglutide vs. semaglutide alone in preclinical models
Of Alzheimer's patients carry APOEA — Halia's HT-4253 targets protective variants that may delay or prevent onset
Of people over 70 carry CHIP mutations, increasing cancer and cardiovascular risk — targeting NEK7 may help mitigate this
